[Federal Register Volume 76, Number 169 (Wednesday, August 31, 2011)]
[Notices]
[Pages 54241-54242]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-22207]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: September 13-14, 2011.
    Time: September 13, 2011, 10:30 a.m. to 5:30 p.m.
    Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will 
review and discuss selected human gene transfer protocols, including 
a protocol that will use a recombinant Saccharomyces cerevisiae that 
expresses the human Brachyury protein in adults with metastatic 
carcinoma. The RAC will also discuss proposed amendments to Section 
III-E-1 of the NIH Guidelines for Research Involving Recombinant DNA 
Molecules (NIH Guidelines), experiments involving partial genomes of 
eukaryotic viruses in tissue culture, and Appendix B of the NIH 
Guidelines, Classification of Human Etiologic Agents by Risk Group. 
Please view the meeting agenda at http://oba.od.nih.gov/

[[Page 54242]]

rdna--rac/rac--meetings.html for more information.
    Place: Hilton Washington/Rockville, 1750 Rockville Pike, 
Rockville, MD 20852.

    Time: September 14, 2011, 8:30 a.m. to 1:15 p.m.
    Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will 
discuss selected human gene transfer protocols, including a study 
using a modified Bifidobacterium longum for targeting of 
chemotherapy for advanced cancer. The RAC will also hear a 
presentation of the results of a Phase 1/2 trial using a modified 
AAV1 virus that expresses the sarcoplasmic reticulum 
Ca2+-ATPase in subjects with advanced heart failure. 
Please view the meeting agenda at http://oba.od.nih.gov/rdna_rac/rac_meetings.html for more information.
    Place: Hilton Washington/Rockville, 1750 Rockville Pike, 
Rockville, MD 20852.
    Contact Person: Chezelle George, Office of Biotechnology 
Activities, Office of Science Policy/OD, National Institutes of 
Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301-496-
9838, [email protected].
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: http://oba.od.nih.gov/rdna/rdna.html, where an agenda and any 
additional information for the meeting will be posted when 
available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)


    Dated: August 22, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-22207 Filed 8-30-11; 8:45 am]
BILLING CODE 4140-01-P